Abstract
<div>AbstractPurpose:<p>Despite the significant association of molecular subtypes with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC), few efforts have been made to identify the underlying pathway(s) responsible for this prognosis. Identifying a clinically relevant prognosis-based gene signature may be the key to improving patient outcomes.</p>Experimental Design:<p>We analyzed the transcriptomic profiles of treatment-naïve surgically resected short-term survivor (STS) and long-term survivor (LTS) tumors (GSE62452) for expression and survival, followed by validation in several datasets. These results were corroborated by IHC analysis of PDAC-resected STS and LTS tumors. The mechanism of this differential survival was investigated using CIBERSORT and pathway analyses.</p>Results:<p>We identified a short-surviving prognostic subtype of PDAC with a high degree of significance (<i>P</i> = 0.018). One hundred thirty genes in this novel subtype were found to be regulated by a master regulator, homeobox gene <i>HOXA10</i>, and a 5-gene signature derived from these genes, including <i>BANF1</i>, <i>EIF4G1</i>, <i>MRPS10</i>, <i>PDIA4</i>, and <i>TYMS</i>, exhibited differential expression in STSs and a strong association with poor survival. This signature was further associated with the proportion of T cells and macrophages found in STSs and LTSs, demonstrating a potential role in PDAC immunosuppression. Pathway analyses corroborated these findings, revealing that this <i>HOXA10</i>-driven prognostic signature is associated with immune suppression and enhanced tumorigenesis.</p>Conclusions:<p>Overall, these findings reveal the presence of a <i>HOXA10</i>-associated prognostic subtype that can be used to differentiate between STS and LTS patients of PDAC and inform on the molecular interactions that play a role in this poor prognosis.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
